Martin Johansson
Vorstandsvorsitzender bei Glactone Pharma AB
Aktive Positionen von Martin Johansson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| University of Lund | Corporate Officer/Principal | - | - |
Glactone Pharma AB
 Glactone Pharma AB Pharmaceuticals: MajorHealth Technology Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden. | Vorstandsvorsitzender | 01.01.2012 | - |
| Gründer | 01.01.2012 | - |
Karriereverlauf von Martin Johansson
Ehemalige bekannte Positionen von Martin Johansson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Respiratorius AB
 Respiratorius AB Pharmaceuticals: MajorHealth Technology Respiratorius AB engages in the development of drug candidates for Chronic Obstructive Pulmonary Disease, asthma, and cancer. The company was founded by Lars Christer Fedrik Fåhraeus and Staffan Skogwall in 1999 and is headquartered in Lund, Sweden. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2006 | - |
| Corporate Officer/Principal | - | 01.01.2011 |
Statistik
International
| Schweden | 4 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Chief Executive Officer | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
 | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Glactone Pharma AB
Glactone Pharma AB Pharmaceuticals: MajorHealth Technology Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden. | Health Technology |
- Börse
- Insiders
- Martin Johansson
- Erfahrung